ProCE Banner Activity

Getting to Know Light-Chain Amyloidosis: My Thoughts on Recent Progress

Clinical Thought
The approval of the anti-CD38 antibody daratumumab has provided a valuable new option for patients with light-chain amyloidosis. Review this expert commentary to get a top-level view of this disease and current best practices.

Released: August 17, 2021

Expiration: August 16, 2022

No longer available for credit.

Share

Faculty

Raymond L. Comenzo

Raymond L. Comenzo, MD

Director, Blood Bank and Stem Cell Processing Laboratory
Tufts Medical Center
Professor of Medicine and Pathology
Tufts University School of Medicine
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Raymond L. Comenzo, MD

Director, Blood Bank and Stem Cell Processing Laboratory
Tufts Medical Center
Professor of Medicine and Pathology
Tufts University School of Medicine
Boston, Massachusetts

Raymond L. Comenzo, MD has disclosed that he received funds for research support from Alnylam, Caelum/Alexion, Janssen, and Sanofi, consulting fees from Abbvie/Genentech, Caelum/Alexion, Janssen, Karyopharm, Sanofi, and Takeda, and royalty from Janssen.